Maynard Um
-
-
-
-
-
-
-
AbbVie presents inflammatory bowel disease data at medical conference
-
-
-
-
-
-
-
AbbVie submits FDA application for SKYRIZI subcutaneous dosing
-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $249 at Guggenheim
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Abbvie (ABBV): today's data "reflective of an opportunity to diversify its business beyond the I&I"
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Abbvie (ABBV)
-
-
-
-
-
-
-
AbbVie submits vitiligo treatment application to FDA and EMA
-
-
-
-
-
-
-
UBS Reiterates Neutral Rating on Abbvie (ABBV)
-
396,356 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

